iTonic Holdings Wins 180-Day Extension to Meet Nasdaq Minimum Bid Rule
iTonic Holdings received a 180-calendar-day extension from Nasdaq to regain compliance with the $1.00 minimum closing bid price rule, extending the deadline to October 19, 2026. Failure to meet the requirement by that date will trigger delisting proceedings and potential review by a Nasdaq hearings panel.
1. Extension Granted by Nasdaq
On April 21, 2026, iTonic Holdings Ltd received approval for a 180-calendar-day extension to satisfy Nasdaq Listing Rule 5550(a)(2), which mandates a minimum $1.00 closing bid price. This extension runs through October 19, 2026, following the expiration of the initial compliance period on April 20, 2026.
2. Delisting Risk and Next Steps
If iTonic’s Class A ordinary shares do not maintain a closing bid price of at least $1.00 by October 19, 2026, Nasdaq will issue a delisting notice. The company may then request a review of the delisting determination by a Nasdaq Hearings Panel.
3. Company Business Focus
Founded in 1998, iTonic, through its subsidiary Beijing Feitian Zhaoye Technology, develops brachytherapy treatment planning systems for targeted radiation cancer therapy. Its lead product helps ensure safe, effective delivery of radioactive sources to kill cancer cells and shrink tumors across multiple malignant applications.